bioMerieux

Valuation Analysis

About the Company

bioMerieux en bref

bioMerieux (BIM.PA) is currently trading at 67,55 € with a market capitalization of 6,9 Md €. The trailing P/E ratio stands at 20.22x, with a forward P/E of 13.73x. The 52-week range spans from 66,25 € to 128,30 €; the current price is 47.3% below the yearly high. Year-over-year revenue growth stands at -2.5%. The net profit margin stands at 9.77%.

💰 Dividende

bioMerieux pays an annual dividend of 0,98 € per share, representing a yield of 1.45%. The payout ratio stands at 26.95%.

📊 Avis des analystes

13 analystes évaluent bioMerieux (BIM.PA) au consensus : Conserver. L'objectif de cours moyen est de 90,20 €, soit un potentiel de +33.53% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 71,60 € à 110,00 €.

bioMerieux : la thèse d'investissement en détail

bioMerieux (BIM.PA) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in France. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

The combination of a 56.73% gross margin and 16.81% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat.

Le scénario baissier

Revenue is contracting at -2.5% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

Valorisation en contexte

The PEG ratio at 1.25 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 7.02x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 13.73x is meaningfully below the trailing 20.22x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 33.53% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy bioMerieux?

Compare top-rated brokers — low fees, trusted providers, fully regulated.